Holen Sie sich die Stockscreener-App
3.88
7.78%
0.28
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Aug Opening: Should I invest in Relmada Therapeutics Inc. before earningsPrice Action & Low Risk Growth Stock Ideas - baoquankhu1.vn
Returns Recap: Can Relmada Therapeutics Inc deliver consistent dividendsQuarterly Portfolio Summary & Safe Entry Point Alerts - baoquankhu1.vn
Momentum Shift: How is The New York Times Company managing supply chain issues2025 Volume Leaders & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00 - Defense World
Stock Recap: Can Culp Inc maintain sales growthDay Trade & Growth Focused Investment Plans - baoquankhu1.vn
Decliners Report: Does Relmada Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Is Office Properties Income Trust in a long term uptrendWeekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Aug Action: Is Orthofix Medical Inc stock a top performer YTD2025 Sector Review & Expert-Curated Trade Recommendations - baoquankhu1.vn
Big Money Moves: Why is Viper Energy Inc stock going downDip Buying & High Conviction Trade Alerts - baoquankhu1.vn
Is Relmada Therapeutics Inc. stock a hidden gemJuly 2025 Review & Low Risk Entry Point Tips - mfd.ru
Take Profit: How do insiders feel about Relmada Therapeutics IncMarket Performance Recap & Detailed Earnings Play Alerts - baoquankhu1.vn
Update Recap: Does Bioventus Inc have a competitive edgeWeekly Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Analysts - MarketBeat
Zacks Research Upgrades Relmada Therapeutics (NASDAQ:RLMD) to "Hold" - MarketBeat
What’s next for Relmada Therapeutics Inc. stockJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - mfd.ru
Resistance Check: What are the analyst revisions for Civitas Resources IncIs STRW stock a good investment in YEAREarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
How do insiders feel about Relmada Therapeutics Inc.Quarterly Growth Report & Fast Entry High Yield Stock Tips - mfd.ru
Leerink Partners Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
Leerink Partners Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential By Investing.com - Investing.com Nigeria
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential - Investing.com Nigeria
Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Relmada Therapeutics (RLMD) Upgraded by Leerink Partners to 'Out - GuruFocus
Targets Report: Is now the right time to enter Relmada Therapeutics IncMarket Risk Analysis & Reliable Price Breakout Alerts - baoquankhu1.vn
Tech Rally: Does Relmada Therapeutics Inc meet Warren Buffetts criteria2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bull Run: Is Relmada Therapeutics Inc in accumulation or distribution phase2025 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline - TipRanks
FDA endorses Relmada’s registrational strategy for bladder cancer therapy - Indian Pharma Post
Is Relmada Therapeutics Inc stock affected by interest rate hikesWeekly Trend Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors - MSN
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Canada
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Footwear buying guidance for all day wear during busy schedules focuses on foot fatigue reduction, making it helpful for judging overall value. - ulpravda.ru
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
Relmada Therapeutics Provides Regulatory Update Confirming - GlobeNewswire
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - ulpravda.ru
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):